Anti-Obesity Pharmacotherapy (Class Effect)

ApprovedSmall molecule

Anti-Obesity Pharmacotherapy (Class Effect) is one of 31 small molecule programs targeting Portal Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Portal HypertensionActive, not recruiting

Portal HypertensionApproved

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Portal Hypertension

#DrugCompanyPhaseTrials

Coreg

Akero Therapeutics

Approved

9 2

Zocor

OOrganon and Co

Approved

4 3

Nexavar

Bayer

Approved

—4

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 5

Sandostatin

Sun Pharma

Approved

1 6

Eliquis

Bristol-Myers Squibb

Phase 3

1 7

Crestor

AstraZeneca

Phase 3

1 8

Octreotide

Johnson & Johnson

Phase 3

—9

Inderal

WWyeth-Lederle Vaccines

Phase 3

4 10

Kuvan

BioMarin Pharmaceutical

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2034

Post-ApprovalRecruiting

Portal Hypertension

NCT07058155

Clinical

Trials by Indication[1]

Portal Hypertension1 trial

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

Recruiting·TThe Cleveland Clinic·Phase 4·NCT07058155·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-Obesity Pharmacotherapy (Class Effect). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-Obesity Pharmacotherapy (Class Effect) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-Obesity Pharmacotherapy (Class Effect). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cleveland Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe Cleveland Clinic

Anti-Obesity Pharmacotherapy (Class Effect)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2034

Trials by Indication[1]

Portal Hypertension1 trial

References

Drug Info

Quick Facts

Related News